Schizophrenia Market: Investment-Ready Growth Trends to 2034 – DelveInsight | Teva Pharma, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharma, Reviva Pharma, Minerva Neurosciences

The Key Schizophrenia Companies in the market include - Teva Pharmaceutical Industries, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Reviva Pharmaceuticals, Minerva Neurosciences, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others.

DelveInsight’s report “Schizophrenia Market Insights, Epidemiology, and Market Forecast-2034” provides a comprehensive analysis of the Schizophrenia landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

 

Additionally, it examines Schizophrenia market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

 

Get a Free sample for the Schizophrenia Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/schizophrenia-market

 

Some of the key facts of the Schizophrenia Market Report:

• The schizophrenia market size was valued at approximately USD 8,000 million in 2024 and is expected to grow at a strong CAGR over the study period (2020–2034).

• Among the 7MM, the United States held the largest schizophrenia market in 2024, valued at nearly USD 6 billion, surpassing the EU4 and the UK as well as Japan. Market dynamics are expected to evolve by 2034 with the introduction of novel emerging therapies for schizophrenia.

• Within the EU4 and the UK, Germany represented the largest market in 2024, with an estimated value of around USD 430 million; however, the UK is projected to overtake Germany by 2034 to become the leading market in the region. In Japan, the schizophrenia market was valued at approximately USD 600 million in 2024, ranking second overall, and is anticipated to grow further by 2034.

• In March 2026, Otsuka Pharmaceutical Canada Inc. (OCPI) and Lundbeck Canada Inc. have achieved broad reimbursement access for ABILIFY ASIMTUFII®, with coverage now extending to more than 90% of Canadians under public drug plans and nearly 60% of those with private insurance. The therapy has been added to formularies across several provinces, including Ontario, Quebec, British Columbia, Nova Scotia, Prince Edward Island, and Alberta, as well as federal programs such as the Non-Insured Health Benefits program.

• In February 2026, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), along with Medincell, announced that the U.S. Food and Drug Administration has accepted their New Drug Application (NDA) for an extended-release injectable suspension of olanzapine (TEV-'749) intended for the treatment of Schizophrenia in adults. The investigational therapy is designed to enhance treatment adherence in real-world settings and support sustained symptom stability, aiming to address a significant unmet need among individuals living with schizophrenia.

• In February 2026, Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) has announced that the U.S. Food and Drug Administration has granted approval for BYSANTI™ (milsaperidone) tablets. The drug is indicated as a first-line treatment for acute manic or mixed episodes linked to Bipolar I disorder, as well as for the treatment of Schizophrenia in adults.

• In January 2026, BioXcel Therapeutics announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for dexmedetomidine (Igalmi) to expand its use for the acute management of agitation related to bipolar disorder or schizophrenia in the at-home (outpatient) setting. The sNDA filing was completed on January 14, 2026.

• In December 2025, Boehringer Ingelheim this week shared additional information on a late-stage clinical trial for an app aimed at addressing under-treated symptoms of schizophrenia and announced plans to submit the app for FDA clearance. Developed in collaboration with Click Therapeutics, the app, CT-155, provides a 16-week digital treatment that incorporates core components of established face-to-face psychosocial therapies for schizophrenia, designed to be used alongside antipsychotic medications. Schizophrenia affects millions in the U.S. and is often characterized by psychotic episodes and delusions.

• In December 2025, Teva Pharmaceuticals has filed a New Drug Application (NDA) with the FDA for olanzapine long-acting injectable (LAI), a once-monthly subcutaneous treatment designed to enhance adherence and stability in individuals with schizophrenia. The investigational therapy, TEV-749, is supported by Phase 3 SOLARIS trial data demonstrating its efficacy, safety, and tolerability in adults aged 18–64 with schizophrenia. Olanzapine LAI is intended to address key treatment gaps and uses proprietary sustained-release technology. Teva emphasizes its commitment to working with the FDA to meet unmet needs in schizophrenia care while strengthening its position in the innovative medicine sector.

• In December 2025, Newron Pharmaceuticals announced the launch of its ENIGMA-TRS 2 Phase 3 clinical trial in the U.S., following FDA and Institutional Review Board approvals. The study will begin at the Semel Translational Research Center for Neuropsychiatry, UCLA. ENIGMA-TRS 2 is a global, 12-week, randomized, double-blind, placebo-controlled Phase 3 trial designed to assess the efficacy, safety, and tolerability of evenamide 15 mg twice daily as an add-on therapy to existing antipsychotics, including clozapine, compared with placebo in patients with treatment-resistant schizophrenia (TRS).

• In September 2025, The FDA approved an injectable extended-release risperidone suspension from Amneal Pharmaceuticals, referencing Janssen Biotech’s Risperdal Consta, for the treatment of schizophrenia. This extended-release formulation is now available in 12.5 mg, 25 mg, 37.5 mg, and 50 mg vials.

• In August 2025, BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company leveraging artificial intelligence to develop innovative neuroscience treatments, announced that it received favorable feedback from the FDA following a pre-sNDA meeting. Based on this guidance, the company believes its planned sNDA submission package will be adequate to support the filing, which is still on schedule for the first quarter of 2026.

• In May 2025, Neurocrine Biosciences initiated a Phase III registrational program to evaluate the investigational oral muscarinic M4 selective orthosteric agonist, NBI-1117568, for treating schizophrenia in adults. This double-blind, placebo-controlled trial will assess the therapy’s safety, tolerability, and efficacy in patients experiencing an acute exacerbation or relapse of schizophrenia symptoms. Approximately 280 participants are expected to be enrolled. The primary endpoint is the reduction in the Positive and Negative Syndrome Scale (PANSS) from baseline, with improvement in the Clinical Global Impression of Severity (CGI-S) scale as a key secondary endpoint.

• In May 2025, Vanda Pharmaceuticals reported that the FDA has accepted the New Drug Application (NDA) for Bysanti™ (milsaperidone) without raising any review concerns. The agency has scheduled February 21, 2026, as the decision date. Milsaperidone, a novel chemical entity and active metabolite of iloperidone, has demonstrated dose-dependent bioequivalence in clinical studies.

• In April 2025, CMG Pharmaceutical, a subsidiary of CHA Biotech, secured FDA approval for Mezofy (formerly Depipzo), an oral film therapy for schizophrenia. Formulated with aripiprazole, it dissolves in the mouth, improving adherence without requiring water.

• In March 2025, Vanda Pharmaceuticals Inc. has submitted a New Drug Application (NDA) to the FDA seeking marketing approval for Bysanti™ (milsaperidone) as a treatment for acute bipolar I disorder and schizophrenia, backed by several clinical studies demonstrating its safety and efficacy.

• In March 2025, LB Pharmaceuticals Inc., a clinical-stage biopharma company focused on developing innovative treatments for neuropsychiatric disorders such as schizophrenia, has shared new positive findings from its NOVA1 Phase 2 clinical trial of LB-102 in patients experiencing acute schizophrenia exacerbations. The data was presented at the 2025 Annual Congress of the Schizophrenia International Research Society (SIRS), currently taking place in Chicago.

• In February 2025, The September 2024 approval of xanomeline-trospium chloride (Cobenfy; Bristol Myers Squibb) marks the first novel schizophrenia treatment in 70 years. While some experts have welcomed the milestone, others remain cautious. Unlike traditional antipsychotics that target dopamine D2 receptors, this therapy works through muscarinic acetylcholine receptors, offering a distinct mechanism of action.

• In January 2025, German pharmaceutical leader Boehringer Ingelheim revealed that its investigational drug iclepertin, intended to treat cognitive impairment in schizophrenia patients, did not meet any primary or secondary endpoints across three Phase III trials. The CONNEX program results showed no significant cognitive or functional improvements over placebo after six months. However, the company noted that iclepertin maintained a favorable safety profile.

• In January 2025, Segal Trials, a private clinical research organization focused on acute schizophrenia and other psychiatric conditions, has shared its enrollment performance data from its involvement in NOVA—a Phase 2 dose-finding study in adults with acute schizophrenia assessing LB-102, a once-daily oral small molecule and potential first-in-class benzamide antipsychotic.

• According to DelveInsight’s analysis, the total number of diagnosed prevalent schizophrenia cases across the 7MM was approximately 3.8 million in 2024, with the United States accounting for nearly 1.4 million of these cases.

• This patient population is expected to increase by 2034, driven by advances in psychiatric research and evolving diagnostic criteria that may enable more accurate identification and diagnosis of schizophrenia worldwide.

• In 2024, the EU4 and the UK together accounted for nearly 42% of the total diagnosed prevalent schizophrenia cases across the 7MM. DelveInsight’s analysis indicates a higher susceptibility to schizophrenia among males, driven by genetic, hormonal, and neurodevelopmental factors. In the United States, diagnosed prevalence in 2024 was approximately 775,000 cases among males and about 670,000 among females, with both figures expected to increase over the forecast period (2025–2034).

• In 2024, severity-based diagnosed prevalent schizophrenia cases across the EU4 and the UK were estimated at approximately 375,000 mild cases, 585,000 moderate cases, and 635,000 severe cases. During the same year, the UK reported around 220,000 prevalent cases among males and nearly 175,000 among females, indicating a higher disease burden in the male population.

• In Japan, total prevalent schizophrenia cases were estimated at about 1 million in 2024, with roughly 790,000 diagnosed. According to DelveInsight’s analysis, the number of diagnosed prevalent cases in Japan is expected to decline, largely due to the country’s shrinking overall population.

• According to the epidemiological model, the prevalence of diagnosed schizophrenia cases across the 7MM varies by severity.

• In 2024, Japan reported approximately 450,000 diagnosed cases of mild schizophrenia, along with around 175,000 moderate cases and 170,000 severe cases. These numbers are expected to shift over the forecast period from 2025 to 2034.

• Key Schizophrenia Companies: Teva Pharmaceutical Industries, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Reviva Pharmaceuticals, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical, Lyndra Therapeutics, Laboratorios Farmacéuticos Rovi, Newron Pharmaceuticals, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others

• Key Schizophrenia Therapies: Olanzapine LAI (TEV-’749), Ulotaront (SEP-363856), Brilaroxazine (RP-5063), Roluperidone (MIN-101/MT-210), REXULTI/RXULTI, CAPLYTA, LONASEN, ABILIFY MYCITE, RP5063 (brilaroxazine), MIN-101 (roluperidone), KarXT (xanomeline-trospium), NUPLAZID (pimavanserin), ICELPERTIN (BI-425809), SEP-363856 (ulotaront), OKEDI (risperidone ISM), LYN-005, NW-3509/NW-3509A (evenamide), CVL-231 (emraclidine), Seroquel Sustained Release, Intramuscular Olanzapine Depot, Xanomeline and Trospium Chloride Capsules, NBI-1117568, and others

• The Schizophrenia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Schizophrenia pipeline products will significantly revolutionize the Schizophrenia market dynamics.

 

Schizophrenia Overview

Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels, and behaves. It is characterized by hallucinations, delusions, disorganized thinking, and impaired social functioning. Symptoms typically appear in late adolescence or early adulthood. The exact cause is unknown but involves a combination of genetic, brain chemistry, and environmental factors. Treatment usually includes antipsychotic medications, psychotherapy, and supportive social services to manage symptoms and improve quality of life.

 

To Know in detail about the Schizophrenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Schizophrenia Market Forecast

 

Schizophrenia Epidemiology

The Schizophrenia epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Schizophrenia Epidemiology Segmentation:

The Schizophrenia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalent Cases of Schizophrenia in the 7MM

• Total Diagnosed Prevalent Cases of Schizophrenia in the 7MM

• Gender-specific Diagnosed Prevalent Cases of Schizophrenia in the 7MM

• Severity-specific Diagnosed Prevalent Cases of Schizophrenia in the 7MM

 

Download the report to understand which factors are driving Schizophrenia epidemiology trends @ Schizophrenia Epidemiology Forecast

 

Schizophrenia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Schizophrenia market or expected to get launched during the study period. The analysis covers Schizophrenia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Schizophrenia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Schizophrenia Therapies and Key Companies

• Olanzapine LAI (TEV-’749): Teva Pharmaceutical Industries/Royalty Pharma/MedinCell

• Ulotaront (SEP-363856): Sumitomo Pharma/Otsuka Pharmaceuticals

• Brilaroxazine (RP-5063): Reviva Pharmaceuticals

• Roluperidone (MIN-101/MT-210): Minerva Neurosciences/Mitsubishi Tanabe Pharma

• REXULTI/RXULTI: Lundbeck

• CAPLYTA: Intra-cellular Therapies

• LONASEN: Sumitomo Pharma

• ABILIFY MYCITE: Otsuka Pharma

• RP5063 (brilaroxazine): Reviva Pharmaceuticals

• MIN-101 (roluperidone): Minerva Neurosciences

• KarXT (xanomeline-trospium): Karuna Therapeutics

• NUPLAZID (pimavanserin): Acadia Pharmaceuticals

• ICELPERTIN (BI-425809): Boehringer Ingelheim

• SEP-363856 (ulotaront): Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical

• OKEDI (risperidone ISM): Laboratorios Farmacéuticos Rovi

• LYN-005: Lyndra Therapeutics

• NW-3509/NW-3509A (evenamide): Newron Pharmaceuticals

• CVL-231 (emraclidine): Cerevel Therapeutics

• Seroquel Sustained Release: AstraZeneca

• Intramuscular Olanzapine Depot: Eli Lilly and Company

• Xanomeline and Trospium Chloride Capsules: Karuna Therapeutics

• NBI-1117568: Neurocrine Biosciences

 

Discover more about therapies set to grab major Schizophrenia market share @ Schizophrenia Treatment Landscape

 

Schizophrenia Market Drivers

• Rising Disease Awareness: Improved understanding of schizophrenia among healthcare providers and patients is increasing diagnosis and treatment rates.

• Advancements in Drug Development: Emergence of novel therapies, including long-acting injectables and drugs with improved safety and efficacy profiles.

• Growing Diagnosed Patient Pool: Enhanced diagnostic criteria and early detection strategies are expanding the treatable population.

• Favorable Regulatory Support: Orphan drug incentives and expedited approval pathways are encouraging innovation in schizophrenia treatments.

• Increased Healthcare Spending: Greater investment in mental health infrastructure across developed markets supports treatment adoption.

 

Schizophrenia Market Barriers

• High Treatment Costs: Long-term therapy and use of branded medications can limit patient access.

• Side Effects and Safety Concerns: Adverse effects associated with antipsychotics impact patient adherence and persistence.

• Poor Treatment Compliance: Stigma and cognitive impairment contribute to non-adherence and treatment discontinuation.

• Limited Disease-Modifying Therapies: Most available treatments manage symptoms rather than address underlying disease mechanisms.

• Market Access Challenges: Variability in reimbursement policies and healthcare infrastructure across regions restricts uniform market growth.

 

Scope of the Schizophrenia Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Schizophrenia Companies: Teva Pharmaceutical Industries, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Reviva Pharmaceuticals, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical, Lyndra Therapeutics, Laboratorios Farmacéuticos Rovi, Newron Pharmaceuticals, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others

• Key Schizophrenia Therapies: Olanzapine LAI (TEV-’749), Ulotaront (SEP-363856), Brilaroxazine (RP-5063), Roluperidone (MIN-101/MT-210), REXULTI/RXULTI, CAPLYTA, LONASEN, ABILIFY MYCITE, RP5063 (brilaroxazine), MIN-101 (roluperidone), KarXT (xanomeline-trospium), NUPLAZID (pimavanserin), ICELPERTIN (BI-425809), SEP-363856 (ulotaront), OKEDI (risperidone ISM), LYN-005, NW-3509/NW-3509A (evenamide), CVL-231 (emraclidine), Seroquel Sustained Release, Intramuscular Olanzapine Depot, Xanomeline and Trospium Chloride Capsules, NBI-1117568, and others

• Schizophrenia Therapeutic Assessment: Schizophrenia current marketed and Schizophrenia emerging therapies

• Schizophrenia Market Dynamics: Schizophrenia market drivers and Schizophrenia market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Schizophrenia Unmet Needs, KOL’s views, Analyst’s views, Schizophrenia Market Access and Reimbursement

 

To know more about Schizophrenia companies working in the treatment market, visit @ Schizophrenia Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Schizophrenia Market Report Introduction

2. Executive Summary for Schizophrenia

3. SWOT analysis of Schizophrenia

4. Schizophrenia Patient Share (%) Overview at a Glance

5. Schizophrenia Market Overview at a Glance

6. Schizophrenia Disease Background and Overview

7. Schizophrenia Epidemiology and Patient Population

8. Country-Specific Patient Population of Schizophrenia

9. Schizophrenia Current Treatment and Medical Practices

10. Schizophrenia Unmet Needs

11. Schizophrenia Emerging Therapies

12. Schizophrenia Market Outlook

13. Country-Wise Schizophrenia Market Analysis (2020–2034)

14. Schizophrenia Market Access and Reimbursement of Therapies

15. Schizophrenia Market Drivers

16. Schizophrenia Market Barriers

17. Schizophrenia Appendix

18. Schizophrenia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Crohn’s Disease Market: Accelerating Growth and Pipeline Impact by 2034 - DelveInsight | Merck, Eli Lilly and Company, RedHill Biopharma, Bristol Myers Squibb, Dr. Falk Pharma GmbH, Janssen-Cilag Ltd

The Key Crohn’s Disease Companies in the market include - Merck, Eli Lilly and Company, RedHill Biopharma, Bristol Myers Squibb, Dr. Falk Pharma GmbH, Janssen-Cilag Ltd., AbbVie, EA Pharma Co., Ltd., Erasmus Medical Center, Takeda, Pfizer, Provention Bio, Inc., Mitsubishi Tanabe Pharma Corporation, and others.

 

DelveInsight’s report, “Crohn’s Disease Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Crohn’s Disease landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

 

Additionally, it examines Crohn’s Disease market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

 

To Know in detail about the Crohn’s Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Crohn’s Disease Market Forecast

 

Some of the key facts of the Crohn’s Disease Market Report:

• The Crohn’s disease market across the seven major markets (7MM) is expected to grow from about USD 11.4 billion in 2025 to nearly USD 16.8 billion by 2034, at a CAGR of 4.40%, driven by key regions including the US, EU4, the UK, and Japan.

• In March 2026, AbbVie announced positive topline findings from the Phase 3 AFFIRM trial, a randomized, double-blind, placebo-controlled study assessing the efficacy and safety of risankizumab subcutaneous induction therapy in adults with moderately to severely active Crohn's disease. Results showed that a significantly higher proportion of patients receiving risankizumab achieved clinical remission based on the Crohn’s Disease Activity Index (55% vs. 30%) and demonstrated endoscopic response (44% vs. 14%) at week 12 compared to placebo. Furthermore, among patients who responded after the initial 12-week induction and continued with maintenance therapy, 67% reached clinical remission and 57% achieved endoscopic response by week 24.

• In March 2026, AbbVie enters the current news cycle with its shares priced at around $234.26 and long-term returns that many investors may consider significant, including gains of about 14.5% over the past year and approximately 167.3% over the last five years. For a company of AbbVie’s scale, new late-stage clinical data in Crohn’s disease along with a recent FDA approval in leukemia could play an important role in shaping investor perspectives regarding the strength of its pipeline and the long-term sustainability of its major franchises.

• In March 2026, Redx Pharma Ltd, based in Alderley Park, UK, announced that the U.S. Food and Drug Administration has granted Fast Track Designation to RXC008 for the treatment of fibrostenotic Crohn’s disease, according to a company press release. RXC008 is a gastrointestinal-restricted pan-ROCK inhibitor currently under development as a potential therapy for this condition. The Fast Track designation is intended to accelerate the development and regulatory review of drugs that address serious diseases with significant unmet medical needs.

• In November 2025, Gomab Therapeutics is advancing its lead candidate, ontunisertib, into a Phase IIb trial after positive results in fibrostenosing Crohn’s disease (FSCD). In the Phase IIa STENOVA study (NCT05843578), the oral activin receptor-like kinase 5 (ALK5) inhibitor demonstrated safety and tolerability over 12 weeks in patients with symptomatic ileal narrowing. Adverse event incidence and severity were comparable between the treatment and placebo groups, and no treatment-emergent cardiac toxicity or inflammation was observed.

• In November 2025, Sandoz’s Tyruko (natalizumab-sztn) is now available for prescription in the U.S. Tyruko is the first FDA-approved biosimilar to Tysabri (natalizumab), indicated for adult patients with relapsing multiple sclerosis and for those with moderate to severe Crohn’s disease. The FDA granted approval in August 2023, with a planned 2024 launch contingent on a second FDA approval for a test detecting anti-JVC antibodies. Natalizumab therapies carry a risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by the John Cunningham virus, which can occur in immunocompromised patients.

• In April 2025, Sanofi decided to discontinue the development of its oral tumour necrosis factor (TNF) inhibitor, balinatunfib, as a standalone treatment after it failed to meet the primary endpoint in a Phase II trial. Preliminary findings from the SPECIFIC-PSO Phase II study (NCT06073119) in psoriasis patients indicated that balinatunfib produced clinically meaningful improvements in the primary endpoint, PASI-75 response, with efficacy similar to other oral psoriasis treatments. However, it did not achieve statistical significance, which Sanofi attributed to “the nature of this limited Phase II study.” PASI-75 is a standard measure assessing whether a patient has achieved a 75% reduction in symptoms from baseline.

• In March 2025, Agomab Therapeutics reported positive interim findings from 44 patients who completed treatment in the ongoing STENOVA1 Phase IIa trial of AGMB-129, an oral gastrointestinal (GI)-restricted small molecule ALK5 (TGF-β RI or ALK5) inhibitor being developed as a potential therapy for Fibrostenosing Crohn’s Disease (FSCD).

• In March 2025, Celltrion announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), after receiving FDA approval in December 2024. STEQEYMA is authorized for the same indications as STELARA, ensuring reliable treatment options for both patients and healthcare providers.

• In March 2025, Johnson & Johnson announced that the FDA has approved TREMFYA® (guselkumab), making it the first and only IL-23 inhibitor offering both subcutaneous (SC) and intravenous (IV) induction options for adults with moderately to severely active Crohn’s disease (CD), a chronic inflammatory condition affecting the gastrointestinal tract.

• In February 2025, Eli Lilly shared findings from the VIVID-2 open-label extension study at the Crohn's and Colitis Congress (CCC), revealing that most patients with moderately-to-severely active Crohn's disease treated continuously with OMVOH for two years achieved sustained clinical and endoscopic outcomes, including 43.8% of patients who had previously failed biologic therapies.

• In January 2025, The FDA approved OMVOH (mirikizumab) for Crohn’s disease, reinforcing the role of IL-23 inhibitors. Demonstrating robust long-term effectiveness, OMVOH is also under investigation for use in pediatric patients, potentially fulfilling a critical unmet need in this group.

• In 2024, the United States accounted for the largest share of the Crohn’s disease market among the seven major markets (7MM), with a value of nearly USD 8,000 million, and it is expected to expand further at a CAGR of about 4.5%. Within Europe, Germany reported the highest Crohn’s disease market size at approximately USD 670 million, while Spain recorded the smallest market at around USD 207 million.

• Meanwhile, Japan’s Crohn’s disease market was valued at nearly USD 423 million in 2024, contributing roughly 4% to the total 7MM market.

• In 2024, the United States reported approximately 1.1 million diagnosed prevalent cases of Crohn’s disease, representing the largest share of the patient population among the seven major markets (7MM).

• The US accounted for nearly 54% of the total diagnosed prevalent cases in the 7MM, while the EU4 and the UK collectively represented around 42%, and Japan contributed about 4% in the same year.

• Among the EU4 countries, Germany recorded the highest number of diagnosed Crohn’s disease cases at nearly 299,000, followed by the UK with approximately 234,000 cases. In contrast, Spain reported the lowest number of cases, with about 93,000 in 2024.

• Additionally, in the United States, around 461,000 cases were classified as mild severity, while nearly 755,000 cases were identified as moderate-to-severe in 2024.

• According to DelveInsight’s estimates, in 2024, the age-specific distribution of diagnosed prevalent Crohn’s disease cases in the United States showed the highest number in the 18–44 years age group, with around 657,000 cases.

• This was followed by the 45–64 years group with approximately 298,000 cases, the 65–84 years group with about 104,000 cases, the 0–17 years group with nearly 81,000 cases, and individuals aged 85 years and above with roughly 11,000 cases.

• Biosimilars have played a major role in shaping the market by lowering treatment costs and expanding patient access to biologic therapies. The first biosimilar to REMICADE received approval in 2016, and it was subsequently followed by additional biosimilars such as INFLECTRA, RENFLEXIS, and AVSOLA.

• Key Crohn’s Disease Companies: Merck, Eli Lilly and Company, RedHill Biopharma, Bristol Myers Squibb, Dr. Falk Pharma GmbH, Janssen-Cilag Ltd., AbbVie, EA Pharma Co., Ltd., Erasmus Medical Center, Takeda, Pfizer, Provention Bio, Inc., Mitsubishi Tanabe Pharma Corporation, and others

• Key Crohn’s Disease Therapies: OMVOH (mirikizumab/LY3074828), ENTYVIO (vedolizumab), Tulisokibart (MK-7240, PRA023), Mirikizumab, RHB-104, ZEPOSIA (ozanimod), budesonide, Guselkumab, Risankizumab SC, E6011, Infliximab, CDPATH™, Etrasimod, PRV-6527, MT-1303, and others

• In 2023, there were about 432,000 cases classified as mild, and approximately 708,000 cases classified as moderate to severe (including those that transitioned from mild to moderate to severe) in the United States.

• The Crohn’s Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Crohn’s Disease pipeline products will significantly revolutionize the Crohn’s Disease market dynamics.

 

Crohn’s Disease Overview

Crohn’s Disease is a chronic inflammatory condition of the digestive tract that can affect any part from the mouth to the anus. It causes symptoms like abdominal pain, diarrhea, weight loss, and fatigue. The exact cause is unknown, but it involves an abnormal immune response, genetics, and environmental factors. Crohn’s Disease is a type of inflammatory bowel disease (IBD) that can lead to complications such as strictures, fistulas, and malnutrition. Treatment focuses on reducing inflammation, managing symptoms, and maintaining remission.

 

Get a Free sample for the Crohn’s Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/crohns-disease-cd-market

 

Crohn’s Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Crohn’s Disease Epidemiology Segmentation:

The Crohn’s Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Diagnosed prevalent cases of Crohn’s disease

• Age-specific diagnosed prevalent cases of Crohn’s disease

• Severity-specific diagnosed prevalent cases of Crohn’s disease

• Treated cases of Crohn’s disease

 

Download the report to understand which factors are driving Crohn’s Disease epidemiology trends @ Crohn’s Disease Epidemiology Forecast

 

Crohn’s Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Crohn’s Disease market or expected to get launched during the study period. The analysis covers Crohn’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Crohn’s Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Crohn’s Disease Therapies and Key Companies

• OMVOH (mirikizumab/LY3074828): Eli Lilly

• ENTYVIO (vedolizumab): Takeda Pharmaceutical

• Tulisokibart (MK-7240, PRA023): Merck

• AGMB-129: Agomab Therapeutics

• TREMFYA: Johnson & Johnson

• SKYRIZI + ABBV-382: Abbvie

• Mirikizumab: Eli Lilly and Company

• RHB-104: RedHill Biopharma

• ZEPOSIA (ozanimod): Bristol Myers Squibb

• budesonide: Dr. Falk Pharma GmbH

• Guselkumab: Janssen-Cilag Ltd.

• Risankizumab SC: AbbVie

• E6011: EA Pharma Co., Ltd.

• Infliximab: Erasmus Medical Center

• CDPATH™: Takeda

• Etrasimod: Pfizer

• PRV-6527: Provention Bio, Inc.

• MT-1303: Mitsubishi Tanabe Pharma Corporation

• E6011: EA Pharma

 

Discover more about therapies set to grab major Crohn’s Disease market share @ Crohn’s Disease Treatment Landscape

 

Crohn’s Disease Market Drivers

• Rising prevalence of Crohn’s disease worldwide: Increasing incidence of inflammatory bowel diseases due to lifestyle changes, genetic predisposition, and environmental factors is significantly driving the demand for effective treatment options.

• Advancements in biologics and targeted therapies: Innovations such as anti-TNF agents, JAK inhibitors, and monoclonal antibodies have improved treatment outcomes, boosting the adoption of advanced therapeutics in the Crohn’s disease market.

• Growing awareness and improved diagnosis rates: Increased patient awareness, improved diagnostic technologies, and early screening initiatives are enabling earlier detection and treatment of Crohn’s disease, expanding the patient pool.

• Increasing investments in R&D and clinical trials: Pharmaceutical companies and research institutions are investing heavily in novel drug development, including microbiome therapies, stem-cell approaches, and personalized medicine.

• Expansion of healthcare infrastructure and reimbursement support: Improved healthcare spending, insurance coverage, and access to specialized care are facilitating the adoption of advanced therapies globally.

 

Crohn’s Disease Market Barriers

• High cost of biologics and advanced therapies: Expensive biologic drugs and long-term treatment regimens place a financial burden on patients and healthcare systems, limiting widespread access.

• Stringent regulatory requirements and long approval timelines: Regulatory agencies require extensive safety and efficacy data for new Crohn’s disease drugs, leading to lengthy and costly development processes.

• Complex and heterogeneous disease nature: Crohn’s disease varies significantly between patients, making it difficult to develop universally effective therapies and complicating clinical trials.

• Side effects and limited long-term efficacy of existing treatments: Conventional therapies may cause adverse effects or lose effectiveness over time, affecting patient adherence and treatment outcomes.

• Limited access to specialized healthcare in some regions: Shortage of trained gastroenterologists and inadequate healthcare infrastructure in developing regions can delay diagnosis and treatment.

 

Scope of the Crohn’s Disease Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Crohn’s Disease Companies: Merck, Eli Lilly and Company, RedHill Biopharma, Bristol Myers Squibb, Dr. Falk Pharma GmbH, Janssen-Cilag Ltd., AbbVie, EA Pharma Co., Ltd., Erasmus Medical Center, Takeda, Pfizer, Provention Bio, Inc., Mitsubishi Tanabe Pharma Corporation, and others

• Key Crohn’s Disease Therapies: OMVOH (mirikizumab/LY3074828), ENTYVIO (vedolizumab), Tulisokibart (MK-7240, PRA023), Mirikizumab, RHB-104, ZEPOSIA (ozanimod), budesonide, Guselkumab, Risankizumab SC, E6011, Infliximab, CDPATH™, Etrasimod, PRV-6527, MT-1303, and others

• Crohn’s Disease Therapeutic Assessment: Crohn’s Disease current marketed and Crohn’s Disease emerging therapies

• Crohn’s Disease Market Dynamics: Crohn’s Disease market drivers and Crohn’s Disease market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Crohn’s Disease Unmet Needs, KOL’s views, Analyst’s views, Crohn’s Disease Market Access and Reimbursement

 

To know more about Crohn’s Disease companies working in the treatment market, visit @ Crohn’s Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Crohn’s Disease Market Report Introduction

2. Executive Summary for Crohn’s Disease

3. SWOT analysis of Crohn’s Disease

4. Crohn’s Disease Patient Share (%) Overview at a Glance

5. Crohn’s Disease Market Overview at a Glance

6. Crohn’s Disease Disease Background and Overview

7. Crohn’s Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Crohn’s Disease

9. Crohn’s Disease Current Treatment and Medical Practices

10. Crohn’s Disease Unmet Needs

11. Crohn’s Disease Emerging Therapies

12. Crohn’s Disease Market Outlook

13. Country-Wise Crohn’s Disease Market Analysis (2020–2034)

14. Crohn’s Disease Market Access and Reimbursement of Therapies

15. Crohn’s Disease Market Drivers

16. Crohn’s Disease Market Barriers

17. Crohn’s Disease Appendix

18. Crohn’s Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Helium 10 Remains a Go-To Toolkit for Amazon and Walmart Sellers in May 2026 - Promo Code SAVE2026 Now Available

Helium 10 offers a range of deals and promotions. Use the exclusive promo code SAVE2026 to claim your discount.

Helium 10 is attracting renewed attention in May 2026 among Amazon, Walmart, and TikTok Shop sellers searching for product research and listing optimisation tools. Those exploring the platform can use promo code SAVE2026 for 20% off sitewide. This article reviews Helium 10's core tools, who the platform is designed for, and what prospective users may wish to consider before subscribing.

Helium 10 Promo Code May 2026: SAVE2026 Unlocks 20% Off for Amazon, Walmart, and TikTok Shop Sellers

Growing interest in e-commerce seller tools has led many entrepreneurs to search for Helium 10 reviews and discount codes in May 2026. Here is an overview of the platform and the current offer.

Searches for Amazon seller software have remained consistently high into 2026, as both new and established e-commerce entrepreneurs look for tools to identify profitable products, optimise listings, and manage the operational demands of selling across multiple marketplaces. Helium 10, a platform offering an extensive suite of tools covering product research, keyword analysis, listing optimisation, advertising, and analytics, is among the most frequently referenced names in this category. For those researching the platform in May 2026, promo code SAVE2026 provides 20% off sitewide when applied at checkout on the official Helium 10 website.

What Is Helium 10?

Helium 10 is a software platform designed for sellers operating on Amazon, Walmart, and TikTok Shop. Its stated aim is to support entrepreneurs at every stage - from those exploring e-commerce for the first time through to established brands and agencies managing large-scale operations. The platform encompasses more than a dozen individual tools, each targeting a specific aspect of the seller workflow, accessible through a single subscription.

The platform also offers educational content, including its Freedom Ticket training series, an Amazon Ads Academy, and a podcast, positioning it as a broader resource for seller development rather than solely a software product.

Key Tools

From a review standpoint, Helium 10's toolset spans several distinct functional areas:

Product Research

• Black Box - A product discovery tool that allows users to filter across Amazon's catalogue using criteria such as estimated revenue, review count, price range, and category. Designed to surface products that may represent viable opportunities.
• Xray - A competitor product analysis tool accessible via the Helium 10 Chrome Extension. Provides estimated sales, revenue, and review data for products viewed on Amazon.
• Chrome Extension - Provides product viability analysis directly within the Amazon browse experience, allowing sellers to assess opportunities without leaving the marketplace.

Keyword Research

• Cerebro - A reverse ASIN lookup tool that allows users to identify the keywords a competitor product is ranking for. Often referenced by sellers assessing keyword gaps and competitive positioning.
• Magnet - A keyword discovery tool for generating keyword lists relevant to a specific product or niche, intended for use during listing creation and optimisation.
• Keyword Tracker - Monitors keyword ranking positions over time, enabling users to assess the impact of listing changes or advertising activity.

Listing Optimisation

• Listing Builder - An AI-assisted tool for creating Amazon product listings, incorporating targeted keywords into titles, bullet points, and descriptions.
• Listing Analyzer - Scores an existing product listing against optimisation benchmarks, identifying areas for potential improvement.
• Product Listing Converter - Exports Amazon product listings to TikTok Shop format, relevant for sellers expanding across marketplaces.

Operations and Analytics

• Profits - A financial performance dashboard that tracks revenue, costs, and profitability at the product level.
• Inventory Management - A forecasting tool for monitoring stock levels and planning replenishment.
• Follow-Up - An automated email sequencing tool for post-purchase communication with customers.
• Alerts - Notifies sellers of changes to their listings, such as title alterations or suppression events.
• Market Tracker - Monitors competitor performance within a defined market segment over time.
• Managed Refund Service - A service focused on identifying and recovering FBA reimbursements owed by Amazon.

Advertising

• Helium 10 Ads - An advertising automation tool designed to manage and optimise Amazon PPC campaigns.
• Influencer Finder - A tool for identifying social media influencers for product promotion purposes.

Who Is Helium 10 Designed For?

Helium 10 serves a broad range of seller profiles. The platform's onboarding pathway distinguishes between new sellers who are exploring e-commerce for the first time, active sellers looking to scale existing operations, enterprise brands, and agencies managing multiple client accounts. This segmented approach reflects the breadth of the tool suite — not all tools will be equally relevant to every user at every stage.

Sellers primarily focused on Amazon FBA are likely to find the widest applicability across the full tool range. Those operating on Walmart or expanding to TikTok Shop will find dedicated marketplace support, though the depth of tooling for Amazon remains the platform's core strength.

Considerations

From a balanced review perspective, individuals evaluating Helium 10 in May 2026 may wish to note:

• The platform's tool suite is extensive, and new users may find the volume of available features requires time to navigate effectively. Helium 10's Academy and Freedom Ticket training resources are specifically designed to address this onboarding curve.
• Helium 10 offers multiple subscription tiers. Users with more focused needs — for example, keyword research only — may wish to evaluate which tier aligns with their current use case before committing to a higher-tier plan.
• Data provided by tools such as Xray and Cerebro represents estimates based on available signals rather than figures sourced directly from Amazon. As with all third-party seller tools, individual results and data accuracy may vary.
• The platform is subscription-based. Users who are still in the early stages of evaluating whether to sell on Amazon may wish to consider beginning with a lower-tier or free-access option before upgrading.

May 2026 Offer: Promo Code SAVE2026

For users considering subscribing to Helium 10 during May 2026, promo code SAVE2026 provides 20% off sitewide. The code can be applied at checkout via the official Helium 10 website at www.helium10.com.

Summary

Helium 10 occupies a well-established position in the Amazon and multi-marketplace seller software category, offering a comprehensive set of tools covering the full seller lifecycle from product discovery through to advertising and operations. Whether the platform represents the right fit will depend on individual seller stage, marketplace focus, and operational needs. The current 20% sitewide discount available via code SAVE2026 throughout May 2026 provides a meaningful reduction for those ready to commit to a subscription.

This article may reference third-party services. Use of the promo code may provide a referral benefit at no additional cost to the reader.

Media Contact
Company Name: Trivas Media
Contact Person: Media Relations
Email:Send Email
Country: United Kingdom
Website: www.helium10.com

GSD Breeder Opens Reservations For German Shepherd Puppies In Wonder Lake, IL

Mittelwest German Shepherds in Wonder Lake, Illinois, has opened reservations for German Shepherd puppies, with current litters available to review online. The kennel focuses on raising well-socialized puppies and helps prospective owners plan for bringing one home.

Wonder Lake, IL - Mittelwest German Shepherds, a GSD breeder in Wonder Lake, Illinois, has opened reservations for upcoming litters of German Shepherd puppies. Prospective buyers can have a clear way to review litters, inquire about availability, and begin planning for bringing a puppy home through the breeder’s website.

What To Know

• Mittelwest German Shepherds breeds and raises GSD puppies at its Wonder Lake, IL, kennel.

• Current and upcoming litters are listed online, with reservations available as puppies become available.

• Prospective buyers can call (815) 653-1900 to ask about availability and next steps.

Mittelwest German Shepherds raises German Shepherd puppies in a kennel environment designed to support early development and socialization. Puppies are introduced to routine handling and basic stimulation before going to their new homes, helping families transition more smoothly during the early stages of ownership.

Those searching for German Shepherd puppies for sale will find that the process starts with reviewing available litters and learning about each puppy’s background. Listings provide insight into parent lines, expected traits, and general availability, giving buyers a clearer sense of what to expect before making a commitment.

Mittelwest German Shepherds also encourages prospective owners to engage directly with the kennel. Conversations typically cover temperament, activity level, and how a puppy may fit into a household, whether for companionship, family life, or more structured working roles.

To see the complete list of available litters, visit https://www.mittelwest.com/for-sale/puppies-for-sale/current-litters/

Beyond breeding, the Wonder Lake facility reflects an ongoing focus on the breed itself. The kennel offers training-related services and opportunities for owners to stay connected, which may be helpful for first-time German Shepherd owners or those looking to continue developing their dog’s skills over time.

For individuals comparing a GSD breeder or considering a German Shepherd puppy for sale, understanding how puppies are raised and what support is available after placement can be just as important as availability. As with any breeding program, timelines vary based on litters and demand, and buyers are encouraged to plan ahead.

“We want people to feel confident not just in the puppy they choose, but in how that puppy was raised and prepared for life at home,” said a representative from Mittelwest German Shepherds.

About Mittelwest German Shepherds

Mittelwest German Shepherds is a Wonder Lake, Illinois-based GSD breeder focused on raising pure-bred German Shepherd dogs for families, companions, and working environments. The kennel serves buyers locally and beyond and provides information on litters, training, and services.

To learn more about available puppies or Mittelwest German Shepherds GSDs, visit the kennel at https://maps.app.goo.gl/azL115en1bq1QMCS6 or give them a call (815) 653-1900.

Media Contact
Company Name: Mittelwest German Shepherds
Contact Person: Julie Martinez
Email:Send Email
Phone: (815) 653-1900
Address:8310 Howe Rd.
City: Wonder Lake
State: IL 60097
Country: United States
Website: https://www.mittelwest.com/

Ultrahuman Expands Health Tracking Ecosystem in May 2026: What Users Need to Know Before Buying - Plus Promo Code SAVE2026

Ultrahuman rings in varying colours displayed in a round, capturing the variants in design with the same core functionality.

Ultrahuman is attracting growing interest in May 2026 among users searching for advanced health tracking tools, including smart rings, continuous glucose monitors, and blood biomarker testing. Those exploring the platform can use promo code SAVE2026 for 10% off sitewide. This article reviews Ultrahuman's product range, key features, and what prospective buyers may wish to consider.

Ultrahuman Promo Code May 2026: SAVE2026 Gets You 10% Off Across the Full Range of Health and Longevity Tracking Products

Interest in wearable health technology and biometric monitoring continues to grow in 2026, with Ultrahuman among the platforms users are researching. Here is an overview of what the brand offers and how to access the current discount.

As the wearable health technology sector expands, more users are searching for platforms that go beyond basic step counting and heart rate monitoring. Ultrahuman, a health technology company with a product range spanning smart rings, continuous glucose monitors, blood biomarker testing, and ambient sleep tracking, has become a notable name in this space. For those researching the brand in May 2026, promo code SAVE2026 applies 10% off sitewide at checkout on the official Ultrahuman website.

What Is Ultrahuman?

Ultrahuman positions itself as a longevity and performance-focused health platform, offering a range of hardware and diagnostic products designed to give users detailed, data-driven insight into sleep, recovery, metabolic health, and overall biomarker status. The company's product ecosystem is built around the concept that meaningful health improvement requires continuous, personalised data - not periodic check-ins.

The platform is built around a companion app that consolidates data across all products into a single interface, with the stated goal of making complex health metrics actionable for the individual user.

Key Products

From a review standpoint, Ultrahuman's current product range includes several distinct categories:

Ring PRO - Ultrahuman's flagship wearable is the Ring PRO, a smart ring designed for continuous sleep and recovery tracking. It monitors metrics including sleep stages, heart rate variability, skin temperature, and movement throughout the night. The ring form factor is notable for its low-profile design relative to wrist-worn alternatives, which users who prefer minimal wearables may find relevant. A prior model, the Ring AIR, established the platform's presence in the smart ring category. Available for pre-release now.

M1 Continuous Glucose Monitor (CGM) - The M1 is a continuous glucose monitoring patch that tracks blood sugar levels in real time. CGM technology, previously used primarily in clinical diabetes management, has attracted interest from a broader wellness audience seeking to understand how diet, exercise, and lifestyle affect metabolic function. Ultrahuman's implementation pairs the hardware with app-based insights and recommendations.

Blood Vision - Blood Vision is Ultrahuman's advanced blood testing service, covering more than 100 biomarkers. Users receive a detailed report interpreted through the platform's analysis tools. The service is positioned toward those seeking a more comprehensive picture of their health beyond standard GP panels.

Ultrahuman Home - The Home device is described as an ambient sleep monitor - a non-wearable option that tracks sleep quality without the need to wear any device. This may appeal to users who find wrist or finger-worn trackers uncomfortable during sleep.

PowerPlugs and Women's Health - The platform also includes PowerPlugs - described as precision micro-tools that add targeted analytical capabilities to the Ring - and a dedicated women's health module covering cycle and ovulation tracking.

App and Data Integration

A notable aspect of the Ultrahuman platform is its unified app, which consolidates data from the Ring, M1, Home device, and Blood Vision into a single interface. For users building a multi-product health stack, this centralised view may reduce the friction of managing data across multiple applications.

Considerations

Users researching Ultrahuman in May 2026 may wish to note the following from a balanced review perspective:

• Ultrahuman's product range spans multiple price points. Users considering the full ecosystem should evaluate which products are most relevant to their specific health goals before purchasing.
• CGM-based glucose monitoring provides a significant volume of data. Users unfamiliar with interpreting metabolic metrics may benefit from reviewing the platform's educational resources before committing.
• As with all wearable health data, individual results will vary and the platform is not a substitute for professional medical advice.

May 2026 Offer: Promo Code SAVE2026

For users considering a purchase during May 2026, the promo code SAVE2026 provides 10% off sitewide at Ultrahuman. The discount applies across the product range via the official website at www.ultrahuman.com.

Summary

Ultrahuman occupies a defined position in the premium health wearables and diagnostics market, with a product ecosystem that spans continuous monitoring, blood testing, and sleep tracking. The platform is likely to be of most interest to users who are actively engaged with health data and seeking granular, ongoing insight into biomarkers and recovery metrics. The current 10% sitewide offer via code SAVE2026 is available throughout May 2026.

This article may reference third-party services. Use of the promo code may provide a referral benefit at no additional cost to the reader.

Media Contact
Company Name: Trivas Media
Contact Person: Media Relations
Email:Send Email
Country: United Kingdom
Website: www.ultrahuman.com

Storage & Logistics Hero: Open Top & Flat Bottom FIBCs - The First Choice for Key Industries

1. What is an Open Top & Flat Bottom FIBC?

As the name suggests, this bulk bag is defined by two core structural features:

Open Top (Full Opening)

The top features a wide, unrestricted opening, usually formed by a tubular body or a full-size top cover. It allows fast, high-volume filling using cranes, forklifts, or direct manual loading.

Flat Bottom

The base is a flat square or rectangular structure, unlike traditional discharge-spout designs. It has no dedicated bottom discharge opening, or only a minor auxiliary opening for sampling or ventilation.

2. Four Core Advantages That Solve Industry Pain Points

This design is not just for show — it is optimized for specific operational needs.

① Ultra-High Filling Efficiency, Time and Labor Saving

Traditional FIBCs with small filling spouts limit loading speed. The wide open top acts like a large-capacity pocket, supporting direct pouring from filling machines, loaders, or manual operation. Filling efficiency is greatly improved, making it ideal for high-volume production.

② Stable Stacking, Safe and Space-Saving

The flat bottom ensures outstanding stability. When filled, the bag stands firmly on the floor or pallet like a solid block. During multi-layer stacking, the flat base creates full contact with the surface above or below, preventing tilting or collapse. This greatly improves safety in storage and transportation while maximizing space utilization.

③ Minimal Residue, Complete Discharge

For high-value or contamination-sensitive materials such as premium plastic pellets, food ingredients, and pharmaceutical intermediates, traditional discharge spouts often leave material trapped in bag corners. Flat bottom FIBCs are typically discharged by cutting or untying stitches for one-time emptying, resulting in extremely low residue. This reduces waste and avoids cross-contamination.

④ Simple Structure, Cost-Effective

By eliminating complex bottom discharge components such as ropes, baffles, and special liners, the production process is simplified. With the same material and load capacity, this type of FIBC offers a more competitive price, helping businesses optimize packaging costs.

3. Ideal Application Scenarios

Open top & flat bottom FIBCs are perfectly matched to the following industries:

✅ Plastics & Chemical Industry

Plastic pellets (PP, PE, ABS, etc.), recycled resins, engineering plastics — fast filling, stable stacking, and complete discharge make this the most classic application.

✅ Mineral & Building Materials Industry

Ore, quartz sand, construction additives, powder additives and other free-flowing materials that do not require precise discharge control benefit greatly from the high-efficiency open-top design.

✅ Food & Feed Industry

Grain, feed raw materials, starch, sugar, salt, etc. Flat bottom design ensures stable stacking for long-term storage and enables clean, hygienic full discharge.

✅ Recycling & Environmental Industry

Waste textiles, plastic flakes, paper scraps and other bulky, irregular recyclables are easy to load through the wide opening, while the flat base keeps storage neat and stable.

Purchasing & Usage Tips

Confirm Discharge Method: Clarify whether you will empty the bag by lifting and pouring or cutting open on a forklift — this determines whether you need extra lifting loops or pallets.

Material & Load Capacity: Select appropriate PP fabric weight and quality based on material characteristics (corrosiveness, sharpness) and target weight. A safety factor of 5:1 or 6:1 is recommended.

Inner Liner Option: For moisture-sensitive goods, use a separate PE liner that can be removed and cut open together during discharge for better protection.

Media Contact
Company Name: Linyi Silk Road International Trade Co., Ltd.
Email:Send Email
Country: China
Website: https://www.slwovenbag.com/

Chef Eddie G Introduces Locavore Pods While Continuing Culinary Media and Educational Initiatives

Chef Eddie G, a culinary professional and media personality, is continuing to expand his work across food storytelling, culinary education, and early-stage platform development. Through his official website, ChefEddieG.TV, Chef Eddie G brings together his culinary background, television projects, and educational initiatives while also participating in the development of Locavore Pods, a new project currently under construction at LocavorePods.com.

The initiatives reflect an ongoing focus on local food culture, culinary accessibility, and opportunities for individuals seeking to turn kitchen skills into income-based activities within their communities.

Chef Eddie G Background

Chef Eddie G is a chef and culinary storyteller whose work spans professional kitchens, media, and food education. His background includes experience in hospitality, recipe development, and culinary media, with a focus on showcasing food traditions and local ingredients.

Chef Eddie G’s official platform, Chefeddieg.org serves as a central resource for his culinary projects, media appearances, and educational programs. The site provides insight into his professional background and ongoing work in food-related initiatives.

Culinary Journeys With Chef Eddie G

Chef Eddie G has participated in culinary television projects that explore food culture, regional ingredients, and cooking techniques. His television work focuses on storytelling through food, highlighting the people, places, and traditions connected to local cuisine.

Through culinary media and television appearances, Chef Eddie G continues to present cooking as a cultural and community-based experience rather than solely a commercial one. His work in this space supports broader conversations around food sourcing, preparation, and hospitality.

Locavore Pods: A New Project in Development

Chef Eddie G is also involved in the development of Locavore Pods, a new project concept currently under construction at LocavorePods.com. Locavore Pods is being developed as a community-oriented platform designed to explore ways home-based cooks and food creators may monetize their kitchens.

The project is conceptually positioned as a professional and community network for food enthusiasts, often described as a “LinkedIn for foodies,” while also drawing comparisons to shared-economy models that support kitchen-based income opportunities. The initiative is focused on enabling individuals to explore culinary entrepreneurship within local and regional frameworks.

Locavore Pods is associated with Chef Eddie G and Michael Henry. The project is expected to begin operations in the United States, with early geographic focus including New York City, Charleston, and Cabo San Lucas. Additional details will be released as development progresses.

Kitchen to Cash Program

In parallel with platform development, Chef Eddie G is associated with the Kitchen to Cash program, an educational initiative highlighted through Chefeddieg.org. The program is designed to help individuals understand how culinary skills and kitchen-based activities may be structured into income-generating opportunities.

Kitchen to Cash aligns with Chef Eddie G’s broader focus on accessibility within the culinary space, supporting individuals who are interested in food entrepreneurship outside traditional restaurant environments.

For any inquiry, contact Michael Henry at Mike@locavorepods.com

About Chef Eddie G

Chef Eddie G is a culinary professional and media participant whose work centers on food culture, local ingredients, and culinary education. Through television, digital platforms, and educational initiatives, he continues to engage audiences interested in cooking, hospitality, and community-based food experiences.

More information is available at https://chefeddieg.org/

Media Contact
Company Name: Locavore Pods
Contact Person: Michael Henry
Email:Send Email
Country: United States
Website: Chefeddieg.org

Healthful Plus Highlights CoreAge Rx NAD+ Injectable as a Leading NAD+ Therapy Option for Longevity and Cellular Wellness

Health and wellness publication Healthful Plus has published a new review article examining the growing interest in NAD+ wellness therapies, with the publication recognizing CoreAge Rx’s NAD+ Injectable as a leading product in the NAD+ injectable therapy category.

The article, published on Healthful Plus, explores how CoreAge Rx’s physician-guided telehealth platform is expanding access to longevity-focused wellness therapies through its NAD+ Injectable treatment. The review discusses the therapy’s delivery method, potential wellness applications, physician oversight model, and growing interest in mitochondrial support and healthy aging solutions.

According to the published review, CoreAge Rx’s NAD+ Injectable is designed as part of a broader “Brain + Body Energy Protocol” focused on supporting cellular energy production, cognitive performance, and metabolic wellness through direct systemic delivery of Nicotinamide Adenine Dinucleotide (NAD+).

NAD+ Injectable is administered through intramuscular or subcutaneous injection and is intended to provide rapid absorption and high bioavailability. CoreAge Rx states that NAD+ plays a critical role in mitochondrial function, DNA repair, metabolic regulation, and healthy cellular aging. The company also notes that natural NAD+ levels decline with age, which may contribute to fatigue, cognitive decline, inflammation, and reduced metabolic efficiency.

The Healthful Plus review highlights several areas associated with the therapy, including support for:

• Cellular energy production
• Mitochondrial efficiency
• Cognitive performance and mental clarity
• Physical stamina and endurance
• DNA repair and cellular resilience
• Healthy aging and long-term wellness support

The article further notes that CoreAge Rx positions the therapy within a physician-guided wellness framework rather than as a standalone wellness product. Patients complete an online health assessment that is reviewed by licensed physicians before treatment approval is considered. If prescribed, therapies are shipped directly to patients through the company’s telehealth platform.

Healthful Plus also highlighted the therapy’s injectable delivery method as a distinguishing feature, noting that injection-based administration bypasses digestive processing for more direct systemic absorption.

According to information referenced in the review, the therapy may also work synergistically with broader wellness approaches such as exercise, fasting protocols, Metformin, and Rapamycin-focused longevity strategies.

The published review additionally referenced Trustpilot feedback cited by the company. Reviewers reportedly praised the platform’s physician responsiveness, accessibility, and patient communication experience.

CoreAge Rx’s NAD+ Injectable is currently available through the company’s physician-guided telehealth platform starting at $299 for a one-month supply.

Read the full review article at: https://healthful-plus.com/inside-coreage-rx-nad-injectable-a-new-option-for-cellular-wellness-support/

Explore the latest products at:

Nad+ Injection: https://www.coreagerx.com/nad-injection/

Nad+ Nasal: https://www.coreagerx.com/nad-nasal/

Anti Aging: https://www.coreagerx.com/anti-aging/

About CoreAge Rx

CoreAge Rx is a LegitScript-certified telehealth platform focused on physician-guided wellness, metabolic support, and longevity-focused therapies. The company offers digital access to wellness treatments designed to support energy, recovery, cognitive performance, and healthy aging through a remote physician-supervised care model.

For more information, visit www.coreagerx.com.

Inquiries can be sent to support@coreagerx.com or called at +1 940-400-4927.

Media Contact
Company Name: CoreAge Rx
Contact Person: Ella Jones
Email:Send Email
Phone: +1 940-400-4927
City: Wichita Falls
State: TX
Country: United States
Website: www.coreagerx.com

Brian Elliott Smith's Bard Up Entertainment Levels Up

Brian E. Smith aka B.E. is experiencing a great start to his 2026 having secured direct distribution deals with Warner Music, Sony/Orchard, and also in the UMG pipeline with CD Baby. He will also be administered through Sony/ATV publishing at the least. He believes that this new deal will allow him to expand his touch points and scale his record label with the major label deals. He knows in this current climate that physical sales will make a return and these deals will help him get into retail stores around the world. He's also reaching to obtain the goal of chart position either nationally or overseas. Currently he still retains ownership of his master recordings, but states if a JV deal makes sense he'll consider making that his next move.

This year he has also gained radio and in-store airplay for his artist Duane Jackson, on-air in over 7 countries and in-store in over 150 countries and 1M locations, respectively. Brian states, “Instead of going platinum in the streets, I went platinum in the suites Lol.” B.E. has stated he is looking for fresh talent as well as reaching back and helping his frequent collaborators with the new deals. “One thing about signing is now I have access to the label artist to potentially write or produce for.” States the lyricist. “I would be lying if I didn't dream of being signed as a kid watching music videos in the 90s. Now I've manifested the opportunity that God put in my heart.”

He's also currently working on Shug Jackson's upcoming album which will be released through Warner. Shug’s current single “Just In Case” which Brian produced is currently being promoted to radio and has been picked up in several terrestrial radio markets. “We're playing ball with the label and working with their marketing and branding department to see how we can leverage and work on the things we came into the deal with already”, says Brian. “Shug and I have goals that align with what the label provides.” B.E. plans to make the most of all 3 deals and is currently in the studio knocking out tracks. He says, “Honestly, I can't wait to get back outside and travel to the hubs for artistic related reasons.” More to come from the rising artist and owner.

More info: BardUpEntertainment.com

Media Contact
Company Name: Bard Up Entertainment
Contact Person: Brian Smith
Email:Send Email
Country: United States
Website: https://bardupentertainment.com/